Background: The frequency and impact of neutralizing antibodies (NAbs) to interferon beta-1b (IFNβ-1b) on clinical and radiographic outcomes is controversial.
Objective: To assess NAb impact in the BEYOND study.
Methods: 2244 patients were randomized (2:2:1) to receive IFNβ-1b, either 250 or 500 µg, or glatiramer acetate, 20 mg, and observed for 2–3.5 years. NAb titers were determined every 6 months. A titer ≥20 NU/ml was considered NAb positive. Efficacy was compared between NAb-positive and NAb-negative patients, using comprehensive statistical analyses, taking into account the delayed appearance of NAbs, the time-dependent changes in the relapse rate, spontaneous reversions to NAb-negative status, NAb-titer level, and also adjusting for baseline factors.
Results: In the IFNβ-1b 250 µg group, NAb-positive titers were detected (≥ once) in 319 patients (37.0%); of these, 112 (35.1%) reverted to NAb-negative status. In the IFNβ-1b 500 µg group, 340 patients (40.7%) became NAb-positive and 119 (35.0%) reverted to NAb-negative status. In both IFNβ groups, especially the 250 µg arm, NAb-positive status was not associated with a convincing impact on any clinical outcome measure by any statistical analysis. By contrast, in both IFNβ groups, NAbs were associated with a very consistent deleterious impact on most MRI outcomes.
Conclusion: There was a notable dissociation between the impact of NAbs on MRI and clinical outcomes. On MRI measures, the impact was consistent and convincing, whereas on clinical measures a negative impact of NAbs was not found. The basis for this clinico-radiographic paradox is unknown but it suggests that the relationship between NAbs and the therapeutic effects of IFNβ-1b is complex.
SchellekensHCasadevallN. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol2004; 251(Suppl. 2): 4–9.
2.
IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology1996; 47: 889–894.
3.
JacobsLDCookfairDLRudickRAHerndonRMRichertJRSalazarAM. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol1996; 39: 285–294.
4.
RudickRASimonianNAAlamJACampionNScaramucciJOJonesW. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology1998; 50: 1266–1272.
5.
PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet1998; 352: 1498–1504.
6.
ClanetMRadueEWKapposLHartungHPHohlfeldRSandberg-WollheimM. A randomized, double-blind, dose-comparison study of weekly interferon-1a in relapsing MS. Neurology2002; 59: 1507–1517.
7.
DurelliLVerdunEBarberoPBerguiMVersinoEGhezziA. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002; 359: 1453–1460.
8.
PanitchHGoodinDSFrancisGChangPCoylePKO’ConnorP. Randomized, comparative study of interferon beta-1a treatment regimens in MS. The EVIDENCE Trial. Neurology2002; 59: 1496–1506.
9.
MalucchiSSalaAGilliFBotteroRDiSapioACapobiancoM. Neutralizing antibodies reduce the efficacy of beta IFN during treatment of multiple sclerosis. Neurology2004; 62: 2031–2037.
10.
KapposLClanetMSandberg-WollheimMRadueEWHartungHPHohlfeldR. Neutralizing antibodies and efficacy of interferon beta-1a. A 4-year controlled study. Neurology2005; 65: 40–47.
11.
SominandaARotUSuoniemiMDeisenhammerFHillertJFogdell-HahnA. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler2007; 13: 208–214.
12.
SørensenPSKoch-HenriksenNRossCClemmesenKMBendtzenKthe Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology2005; 65: 33–39.
13.
PetkauAJWhiteRAEbersGCRederATSibleyWALublinFD. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler2004; 10: 126–138.
14.
RiceGPPasznerBOgerJLesauxJPatyDEbersG. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology1999; 52: 1277–1279.
15.
BellomiFScagnolariCTomassiniVGasperiniCPaolilloAPozzillicC. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci2003; 215: 3–8.
16.
RederAEbersGTraboulseeALiDLangdonDGoodinDthe 16-Year Long-Term Follow-up Study Investigators. Cross-sectional study assessing long-term safety of interferon-β -1b for relapsing–remitting MS. Neurology2010; 74: 1877–1885.
17.
PachnerARWarthJDPaceAGoelzSthe INSIGHT Investigators. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology2009; 73: 1493–1500.
18.
PachnerARDailDPakENarayanK. The importance of measuring IFNβ bioactivity: monitoring in MS patients and the effect of anti-IFNβ antibodies. J Neuroimmunol2005; 166: 180–188.
19.
PachnerARNarayanKPakE. Multiplex analysis of expression of three IFNβ-induced genes in antibody-positive MS patients. Neurology2006; 66: 444–446.
20.
PrenticeRL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med1989; 8: 431–440.
21.
Weinstock-GuttmanBRansohoffRMKinkelRPRudickRA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol1995; 37: 7–15.
22.
GilliFBertolottoASalaAHoffmannFCapobiancoMMulucchiS. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain2004; 127: 259–268.
23.
DeisenhammerFReindlMHarveyJGasseTDilitzEBergerT. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology1999; 52: 1239–1243.
24.
HesseDSellebjergFSørensenPS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology2009; 73: 372–377.
25.
HemmerBStüveOKieseierBSchellekensHHartungHP. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol2005; 4: 403–412.
26.
GoodinDSFrohmanEMHurwitzBO’ConnorPWOgerJJRederAT. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology2007; 68: 977–984.
27.
GoodinDSHurwitzBNoronhaA. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res2007; 35: 173–187.
28.
GoodinDS. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. (Correspondence). J Int Med Res2008; 36: 208–210.
29.
FarrellRBendtzenKBertolottoAClarkBComabellaMDeisenhammerF. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. (Correspondence). J Int Med Res2008; 36: 204–208.
30.
PachnerAR. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. (Correspondence). Neurology2007; 69: 1555–1556.
31.
PolmanCHDeisenhammerFGiovannoniGKillesteinJSchellekensH. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. (Correspondence). Neurology2007; 69: 1553–1555.
32.
SørensenPSBertolottoA. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. (Correspondence). Neurology2007; 69: 1552–1553.
33.
PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology2001; 56: 1628–1636.
34.
PolmanCKapposLWhiteRDahlkeFBeckmannKPozzilliC. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology2003; 60: 37–43.
35.
SørensenPSRossCClemmesenKMBendtzenKFrederiksenJLJensenKDanish Multiple Sclerosis Study Group. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing–remitting multiple sclerosis. Lancet2003; 362: 1184–1191.
36.
PanitchHMillerAPatyDWeinshenkerB. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology2004; 63: 1788–1795.
37.
FrancisGSRiceGPAlsopJC. PRISMS Study Group. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology2005; 65: 48–55.
38.
PachnerARCadavidDWolanskyLSkurnickJ. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology2009; 73: 1485–1492.
39.
PachnerAR. Anti-IFNβ antibodies in IFNβ-treated MS patients: summary. Neurology2003; 61: S1–S5.
40.
RotUSominandaAFogdell-HahnAHillertJ. Impression of clinical worsening fails to predict interferon-beta neutralizing antibody status. J Int Med Res2008; 36: 1418–1425.
41.
O’ConnorPFilippiMArnasonBComiGCookSGoodinD. 250 microgram or 500 microgram interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol2009; 8: 889–887.
42.
McDonaldWICompstonAEdanGGoodkinDHartungHPLublinFD. Recommended diagnostic criteria for Multiple Sclerosis: guidelines from the International Panel on the diagnosis of Multiple Sclerosis. Ann Neurol2001; 50: 121–127.
43.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
44.
FilesJGGrayJLDoLTFoleyWPGabeJDNestaasE. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res1998; 18: 1019–1024.
45.
McKayFSchibeciSHeardRStewartGBoothD. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort. J Immunol Methods2006; 310: 20–29.
46.
ZegerSLLiangKY. An overview of methods for the analysis of longitudinal data. Stat Med1992; 11: 1825–1839.
47.
BarberoPBerguiMVersinoERicciAZhongJJFerreroB. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial II): analysis of MRI responses to treatment and correlation with NAb. Mult Scler2006; 12: 72–76.
48.
FreedmanMSEdanGHartungHPKapposLMillerHMontalbánXfor the BENEFIT Study Group. The impact of neutralizing antibodies within 5 years of treatment with interferon beta-1b initiated at the first event suggestive of multiple sclerosis. Neurology2009; 72(Suppl. 3): A197–A198.
49.
GoodinDSTraboulseeARederALiDLangdonDKnappertzV., and the 16-Year Long-Term Follow-up Study Investigators. Early treatment with interferon beta-1b is associated with improved long-term outcome in multiple sclerosis. Poster P52 presented at the World Congress on Treatment and Research in Multiple Sclerosis, the 1st Joint Meeting of ACTRIMS, ECTRIMS and LACTRIMS, Montréal, Canada, 17–20 September 2008. Mult Scler2008; 14 (Suppl 1):S44, Abstract P52.
50.
BenjaminiYHochbergY. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B1995; 57: 289–300.
51.
BarkhofF. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol2002; 15: 239–245.
52.
GoodinDS. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?. Ann Neurol2006; 59: 597–605.
53.
GoodinDSLiDTraboulseeTRederAJonesJBeckmannK., and the Interferon Beta-1b 16-Year Long-Term Follow-Up Study. Predictive clinical and magnetic resonance imaging markers. Poster P02.142 presented at the 60th annual meeting of the American Academy of Neurology (AAN), Chicago, IL, USA, 12–19 April 2008. Neurology2008; 70 (Suppl 1): A85, Abstract P02.142.
54.
LangdonDRederAGoodinDTraboulseeALiDBeckmannK. Expanded Disability Status Scale and magnetic resonance imaging burden of disease predict cognitive status at 16 years: data from the Interferon Beta-1b Long Term Follow-Up Study. Poster P04.155 presented at the 60th annual meeting of the American Academy of Neurology (AAN), Chicago, IL, USA, 12–19 April 2008. Neurology2008; 70 (Suppl 1): A208, Abstract P04.155.
55.
KapposLMoeriDRadueEWSchoetzauASchweikertKBarkhofFfor the Gadolinium MRI Meta-analysis Group. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet1999; 353: 964–969.
56.
MolyneuxPDBarkerGJBarkhofFBeckmanKDahlkeFFilippiMfor the European Study Group on Interferon Beta-1b in Secondary Progressive MS. Clinical–MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology2001; 57: 2191–2197.
57.
SormaniMPBruzziPComiGFilippiM. MRI metrics as surrogate markers for clinical relapse rate in relapsing–remitting MS patients. Neurology2002; 58: 417–421.
58.
SormaniMPBonzanoLRoccatagliataLCutterGRMancardiGLBruzziP. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol2009; 65: 268–275.
59.
IFNβ Multiple Sclerosis Study Group. Interferon-beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized double-blind, placebo-controlled trial. Neurology1993; 43: 655–661.
60.
ComiGFilippiMWolinskyJSthe European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol2001; 49: 290–297.
